Home > Insider Trading > Filing (0001104659-16-131586)

Filing Details

Accession Number:: 0001104659-16-131586
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-07 17:41:46
Reporting Period:: 2016-07-06

Filing Date:: 2016-07-07
Accepted Time:: 2016-07-07 17:41:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	Pharmaceutical Preparations (2834)	453772460

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1575843	Amir Nashat	C/O Syros Pharmaceuticals, Inc. 620 Memorial Drive, Suite 300 Cambridge MA 02139		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-06	1,164,486	$0.00	1,164,486	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	22,167	$0.00	22,167	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	373,847	$12.50	1,538,333	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	26,153	$12.50	48,320	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	4,366,825	$0.00	1,164,486	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	83,129	$0.00	22,167	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. PMC VII disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein. Amir Nashat ("Nashat") is a member of the Issuer's Board of Directors. Nashat may be deemed to have shared voting and dispositive power of the shares held by PP VII. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. PMC VII disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein. Nashat may be deemed to have shared voting and dispositive power of the shares held by PEF VII. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.